// App-Quantinova.ai

347 : To assess the clinical effect of radium 223 (Ra223) in patients with progressive symptomatic bone metastases on a background of metastatic castrate resistant prostate cancer (mCRPC).

Researchers

Presenter

  • Christina J. Hague

Principal Investigators

  • Charlotte Fisher

  • James Wylie

  • Ananya Choudhury

  • Tony Elliot

  • Anna Tran

  • Catherine Coyle

  • Ruth Conroy

  • John P. Logue

Medical Centers

  • The Christie Hospital, Manchester, United Kingdom

  • The Christie Hospital, Manchester, United Kingdom

  • The Christie NHS Foundation TRUST, Manchester, United Kingdom

  • The Christie NHS Foundation TRUST, Manchester, United Kingdom

  • The Christie Hospital, Manchester, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

  • Bone metastases

  • Prostate cancer

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved